South Korea's Drug Approvals In 2016: An Infographic
South Korea is actively pursuing an innovation agenda with a goal to transform into a major pharma country, but it seems to have a long way to go as most of last year’s novel drug approvals were for imported drugs. Approvals for incrementally modified drugs surged amid a fall in novel drug compound candidates.
You may also be interested in...
New South Korean President Moon Jae-in appears likely to continue to nurture the pharma and biotech industries by generally favorable policies such as improving the domestic drug pricing system to aid the global market entry of locally-originated novel drugs, and looks set to consider industry proposals for a new government R&D ‘control tower’.
Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.